Indeed, many drugs used to treat essential hypertension ultimately decrease renal ENaC activity, either indirectly by reducing the activity of the renin–angiotensin–aldosterone system (RAAS) or more directly by inhibiting the mineralocorticoid receptor (MR) or the channel itself. Here, NR3C2 is linked to hypertensive disorder.